Longboard Pharmaceuticals (Longboard Pharmaceuticals) Cash-to-Debt : 80.62 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Longboard Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Longboard Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2024 was 80.62.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Longboard Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Longboard Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

LBPH' s Cash-to-Debt Range Over the Past 10 Years
Min: 80.62 Med: 149.13 Max: No Debt
Current: 80.62

During the past 4 years, Longboard Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 80.62. And the median was 149.13.

LBPH's Cash-to-Debt is ranked better than
76.88% of 1527 companies
in the Biotechnology industry
Industry Median: 6.23 vs LBPH: 80.62

Longboard Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Longboard Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Longboard Pharmaceuticals Cash-to-Debt Chart

Longboard Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

203.67

91.34

102.10

Longboard Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial												111.46	107.04	111.59	102.10	80.62

Competitive Comparison of Longboard Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Longboard Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longboard Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longboard Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Longboard Pharmaceuticals's Cash-to-Debt falls into.

Longboard Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Longboard Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	48.498	/	(0.475	+	0)
	=	102.10

Longboard Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	321.043	/	(0.315	+	3.667)
	=	80.62

Longboard Pharmaceuticals (NAS:LBPH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Longboard Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Longboard Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Longboard Pharmaceuticals (Longboard Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longboard Pharmaceuticals Inc (NAS:LBPH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4275 Executive Square, Suite 950, La Jolla, CA, USA, 92037

Website

https://www.longboardpharma.com

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.

Executives

Randall Kaye	officer: CMO	11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Jane Tiller	director	C/O LONGBOARD PHARMACEUTICALS, INC., 4275 EXECUTIVE DRIVE, SUITE 950, LA JOLLA CA 92037
Brandi Roberts	officer: Chief Financial Officer	12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Phillip M Schneider	director	GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121
Vincent Aurentz	director	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Kevin Robert Lind	director, officer: President and CEO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Paul J Sekhri	director	C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Casey Lynch	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Le Goff Corinne	director	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Arena Pharmaceuticals Inc	10 percent owner	6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Philip Perera	officer: Chief Medical Officer	C/O LONGBOARD PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121